CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 10.72: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.25%
Annual Rate
CNY 0.16Paid annual
Payout Ratio
25.6%Sustainable
Last Ex-Dividend
Jul 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.22BCNY927.40M · vs all stocks (USD)
Trailing P/E
51.48xvs Biotechnology peers
Revenue (TTM)
939.31MCNY140.16M · vs all stocks (USD)
Profit Margin
12.80%vs Biotechnology peers
Beta
0.4030xvs all stocks
52-Week Change
17.22%vs all stocks
Market Capitalization
6.22BCNY927.40M · vs all stocks (USD)
Enterprise Value
4.52BCNY674.04M · vs all stocks (USD)
Trailing P/E
51.48xvs Biotechnology peers
Forward P/E
35.55xvs Biotechnology peers
Price to Sales (TTM)
6.62xvs Biotechnology peers
Price to Book (MRQ)
3.08xvs Biotechnology peers
Enterprise to Revenue
4.81xvs Biotechnology peers
Enterprise to EBITDA
39.41xvs Biotechnology peers
Gross Margin
30.15%vs Biotechnology peers
Profit Margin
12.80%vs Biotechnology peers
Operating Margin
10.04%vs Biotechnology peers
Return on Assets (TTM)
3.06%vs Biotechnology peers
Return on Equity (TTM)
6.26%vs Biotechnology peers
Revenue (TTM)
939.31MCNY140.16M · vs all stocks (USD)
Revenue per Share (TTM)
9.75CNYUpdated Sep 21, 2026Quarterly Revenue Growth
20.80%vs Biotechnology peers
Gross Profit (TTM)
295.11MCNY44.04M · vs all stocks (USD)
EBITDA (TTM)
137.15MCNY20.47M · vs all stocks (USD)
Net Income (TTM)
120.25MCNY17.94M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-38.30%vs Biotechnology peers
Operating Cash Flow (TTM)
63.60MCNY9.49M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.72MCNY256.25K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1603CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.25%vs all stocks
Payout Ratio
25.63%vs Biotechnology peers
Minority Interest (Equity)
7.56MCNYFY2025 · Dec 31, 2025Revenue
851.01MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
555.36MCNYFY2025 · Dec 31, 2025Gross Profit
295.64MCNYFY2025 · Dec 31, 2025Operating Income
135.02MCNY20.15M · vs all stocks (USD)
Pre-tax Income
155.15MCNYFY2025 · Dec 31, 2025Income Tax Expense
16.85MCNYFY2025 · Dec 31, 2025Net Income
138.29MCNYFY2025 · Dec 31, 2025EBIT
158.01MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
188.17MCNYFY2025 · Dec 31, 2025Research & Development
61.97MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
64.04MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.98MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
11.10MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.86MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
138.29MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.39MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
101.29MCNYFY2025 · Dec 31, 2025Free Cash Flow
82.03MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.12BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
138.29MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.37MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-49.72MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.35MCNYFY2025 · Dec 31, 2025Capital Expenditures
-19.26MCNYFY2025 · Dec 31, 2025Net Acquisitions
-24.00MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.23BCNYFY2025 · Dec 31, 2025Sale of Investments
2.29BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
19.11MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-55.14MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-11.78MCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.11MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-69.03MCNYFY2025 · Dec 31, 2025Shares Outstanding
96.58MSharesUpdated Sep 21, 2026Float Shares
38.00MSharesUpdated Sep 21, 2026% Held by Insiders
60.00%vs all stocks
% Held by Institutions
10.49%vs all stocks
Total Cash (MRQ)
1.67BCNY249.52M · vs all stocks (USD)
Total Cash per Share (MRQ)
17.45CNYUpdated Sep 21, 2026Total Debt (MRQ)
16.32MCNY2.43M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0081xvs Biotechnology peers
Current Ratio (MRQ)
5.81xvs Biotechnology peers
Book Value per Share (MRQ)
20.86CNYUpdated Sep 21, 2026Total Assets
2.40BCNY358.07M · vs all stocks (USD)
Total Current Assets
2.16BCNYFY2025 · Dec 31, 2025Total Liabilities
423.89MCNYFY2025 · Dec 31, 2025Total Non-current Assets
244.34MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
38.81MCNYFY2025 · Dec 31, 2025Total Current Liabilities
385.07MCNYFY2025 · Dec 31, 2025Cash
1.11BCNYFY2025 · Dec 31, 2025Cash Equivalents
14.02MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.13BCNYFY2025 · Dec 31, 2025Other Short-term Investments
620.12MCNYFY2025 · Dec 31, 2025Accounts Receivable
133.47MCNYFY2025 · Dec 31, 2025Inventory
59.02MCNYFY2025 · Dec 31, 2025Accounts Payable
46.17MCNYFY2025 · Dec 31, 2025Short-term Debt
36.80MCNYFY2025 · Dec 31, 2025Other Current Liabilities
20.12MCNYFY2025 · Dec 31, 2025Long-term Debt
7.73MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
779.00CNYFY2025 · Dec 31, 2025Common Stock (Book)
96.58MCNYFY2025 · Dec 31, 2025Retained Earnings
801.09MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.98BCNY294.82M · vs all stocks (USD)
Treasury Stock
22.95MCNYFY2025 · Dec 31, 202552-Week Low
43.79CNYUpdated Sep 21, 202652-Week High
91.78CNYUpdated Sep 21, 202652-Week Change
17.22%vs all stocks
Beta
0.4030xvs all stocks
50-Day MA
55.83CNYUpdated Sep 21, 2026200-Day MA
60.74CNYUpdated Sep 21, 2026Avg 10-Day Volume
3.48MSharesUpdated Sep 21, 2026Avg 30-Day Volume
3.83MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
1.25CNYUpdated Sep 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Working Capital Pattern
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 10.72: safe zoneNotable
Altman Z-Score: 10.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Bailing Group Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Future Corporation
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesRevenue Growing With Receivables GrowingWorking Capital PatternMulti-Year FCF With Growth And Margin
Indian Hotels Company Ltd.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesRevenue Growing With Receivables GrowingWorking Capital PatternMulti-Year FCF With Growth And Margin
One Career Inc.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesRevenue Growing With Receivables GrowingWorking Capital PatternMulti-Year FCF With Growth And Margin